Two-Dose J&J Vaccine 94% Effective Against COVID-19: Study

The US pharma giant Johnson & Johnson said on Tuesday that a Phase 3 study proved that its single-dose vaccine gave 94% protection against symptomatic COVID-19 disease when coupled with a booster shot administered two months later.

Moscow: The US pharma giant Johnson & Johnson said on Tuesday that a Phase 3 study proved that its single-dose vaccine gave 94% protection against symptomatic COVID-19 disease when coupled with a booster shot administered two months later.

“Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases,” the company’s R&D chief Mathai Mammen said.

The company said that antibody levels rose from four to six times higher after a booster shot was given two months after the first dose, compared to antibody levels observed after the first shot. When administered six months after the first shot, the booster increased antibody levels ninefold within one week. Antibodies continued to climb to twelve-fold four weeks after the booster.

Source
UNI

We welcome your comments, questions, corrections and additional information relating to this article. Your comments may take some time to appear. Please be aware that off-topic comments will be deleted. If you need specific help with your account, feel free to contact our Support Team. Thank you.

Check Also
Close
Back to top button

Adblocker Detected

Please turn off your Adblocker to continue using our service.